MedTrace Logo

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

NCT01349075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 474

Last updated 2025-04-29

No results posted yet for this study

Summary

TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue.

Conditions

Interventions

RADIATION

TheraSphere

The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.

Sponsors & Collaborators

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Colette Shaw, MD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2021-03-15
Completion
2021-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01349075 on ClinicalTrials.gov